CGT Access Models: Buy & Bill vs. Specialty Pharmacy
Establishing the right commercialization strategy for cell and gene therapies (CGTs), including channel access, from the start is essential to supporting treatment center participation and expanding patient access over time. Explore the differences between the Buy & Bill and Specialty Pharmacy models, and how each approach affects financial risk, payer coordination, and operational complexity.
Why Channel Strategy is a Critical Choice
Financial Implications
Channel selection determines who carries upfront cost of the therapy, reimbursement risk, and cash-flow exposure.
Operational Burden
Channel strategy affects more than reimbursement. Responsibilities for insurance verification, payer coordination and administrative execution shift significantly between Buy & Bill and Specialty Pharmacy models.
Access & Adoption
Channel planning influences which treatment centers can participate and how quickly networks expand.
Strategic Channel Design for Sustainable CGT Growth
Channel strategy is more than a distribution decision. It shapes financial risk allocation, reimbursement complexity, and treatment center participation. Optionality expands the provider network, increases flexibility across care settings, and creates more access points for patients.
It's a win-win. Treatment centers are empowered to select the model that fits their operational and financial needs, and biopharma companies can expand their treatment networks quickly, accelerating access.
Learn how InspiroGene can help.